8-K: Oramed Pharmaceuticals Secures Deferral on Scilex Debt, Gains Equity and Royalty Rights

Oramed Pharmaceuticals has agreed to defer a debt payment from Scilex Holding Company in exchange for shares, royalty rights, and potential future funding opportunities.

Summary

• Oramed Pharmaceuticals and other investors have agreed to defer a $6.25 million debt payment due from Scilex Holding Company from January 2, 2025, to January 31, 2025.
• In exchange for this deferral, Scilex's subsidiary, SCLX JV, will provide 5 million shares of Oramed stock to the investors, with 2.5 million shares going to Oramed.
• The payment is further deferred to October 8, 2026, after Scilex pays $1.11 million to the investors.
• The investors will also receive a 4% royalty on worldwide net sales of Gloperba and Elyxyb (excluding Elyxyb sales in Canada) for 10 years.
• The investors have the option to fund up to 50% of the purchase price for ex-US product rights and receive revenue proportional to their investment.
• The agreement is contingent on Scilex extending the maturity of a separate $25 million debt to Oramed from March 21, 2025, to December 31, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the agreement provides Oramed with potential future revenue and equity, it also highlights Scilex's financial challenges and the complexity of the deal. The deferral of debt payments and the need for further extensions suggest some underlying financial concerns.

Positives

• Oramed receives 2.5 million shares of its own stock, potentially increasing its value.
• The deferral of the debt payment provides Scilex with additional financial flexibility.
• The 4% royalty on Gloperba and Elyxyb sales provides a long-term revenue stream for the investors.
• The option to fund ex-US product rights offers potential for further revenue generation.
• The agreement avoids potential defaults on the Tranche B Notes.

Negatives

• The initial debt payment is deferred, not eliminated, indicating potential financial strain at Scilex.
• The agreement is contingent on Scilex extending another debt payment, adding complexity and risk.
• The royalty is subject to the sales performance of Gloperba and Elyxyb.
• The funding of ex-US product rights is optional, requiring further investment from the investors.

Risks

• Scilex's ability to meet its financial obligations remains a concern, as evidenced by the need for payment deferrals.
• The success of the royalty agreement depends on the sales performance of Gloperba and Elyxyb.
• The extension of the $25 million debt payment is not guaranteed and is subject to Oramed's approval.
• The agreement is complex and involves multiple parties and conditions, increasing the risk of unforeseen issues.

Future Outlook

The agreement provides a framework for future revenue through royalties and potential ex-US product rights, but is contingent on Scilex's financial stability and the successful commercialization of Gloperba and Elyxyb. The extension of the $25 million debt is also critical for the agreement to be fully realized.

Management Comments

• The document includes a statement from Oramed's CEO, Nadav Kidron, confirming the agreement.

Industry Context

This announcement reflects the complex financial arrangements common in the pharmaceutical industry, where companies often use debt and equity financing to fund development and commercialization. The royalty agreement is a typical method for investors to share in the potential success of a product.

Comparison to Industry Standards

• The use of convertible notes and royalty agreements is a common practice in the biotech and pharmaceutical industries, particularly for companies in the development stage.
• The 4% royalty rate is within the typical range for pharmaceutical products, although specific rates can vary widely based on the product, market, and stage of development.
• The deferral of debt payments and the issuance of equity are also common strategies for companies facing short-term financial challenges.
• Companies like Royalty Pharma and Ligand Pharmaceuticals are examples of firms that specialize in royalty financing, and their deal structures can be used as benchmarks for comparison.

Stakeholder Impact

• Shareholders of Oramed may see a positive impact from the receipt of shares and potential royalty revenue.
• Scilex benefits from the deferral of debt payments, providing short-term financial relief.
• The agreement could impact the value of Scilex's debt and equity.
• The agreement could impact the future development and commercialization of Gloperba and Elyxyb.

Next Steps

• Scilex needs to secure an agreement to extend the maturity of its obligations under the Senior Secured Promissory Note to December 31, 2025.
• The parties need to finalize the agreement for the royalty and exclusive rights.
• The 5 million shares of Oramed stock need to be delivered to the investors.
• The investors will need to decide whether to fund the ex-US product rights.

Key Dates

Keywords

debt deferral, convertible note, royalty, equity, Scilex, Oramed, Gloperba, Elyxyb, Tranche B Notes, SCLX JV